In the BioHarmony Drug Report Database
Prochlorperazine
Compazine (prochlorperazine) is a small molecule pharmaceutical. Prochlorperazine was first approved as Compazine on 1982-01-01. It is used to treat anxiety disorders, dementia, nausea, psychotic disorders, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor and D(3) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor, D(4) dopamine receptor, and protein S100-A4.
Trade Name
|
Compazine |
|---|---|
Common Name
|
prochlorperazine |
ChEMBL ID
|
CHEMBL728 |
Indication
|
anxiety disorders, dementia, nausea, psychotic disorders, schizophrenia, vomiting |
Drug Class
|
Typical antipsychotic |
Image (chem structure or protein)